Baxter Pays $150 Mil. For Somatogen Recombinant Hemoglobin Technology
Baxter will pay about $150 mil. for a chance to apply Somatogen's recombinant hemoglobin technology to its blood substitute program.
You may also be interested in...
The acquisition of Apex Bioscience by Munich-based start-up VitaResc Biotech AG will provide for the financing of a Phase III program in nitric oxide-induced shock with Apex' lead product, pyridoxalated hemoglobin polyoxyethylene.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011